Michael Ackermann - Tarsus Pharmaceuticals CoFounder Board

Tarsus Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.2726) % which means that it has lost $0.2726 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5956) %, meaning that it created substantial loss on money invested by shareholders. Tarsus Pharmaceuticals' management efficiency ratios could be used to measure how well Tarsus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.55 in 2024. Return On Capital Employed is likely to drop to -0.66 in 2024. At this time, Tarsus Pharmaceuticals' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 1.6 M in 2024, whereas Total Assets are likely to drop slightly above 165.9 M in 2024.

Similar Executives

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. Tarsus Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 46 people. Tarsus Pharmaceuticals (TARS) is traded on NASDAQ Exchange in USA. It is located in 15440 Laguna Canyon Road, Irvine, CA, United States, 92618 and employs 244 people. Tarsus Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Tarsus Pharmaceuticals Leadership Team

Tarsus Stock Performance Indicators

Additional Tools for Tarsus Stock Analysis